Abstract
Several studies were conducted to explore the prognostic significance of podocalyxin-like protein (PODXL) expression in various cancers, with contradictory. This study aims to summarize the prognostic significance of PODXL expression in cancers. PubMed, the Cochrane Library and Embase were completely retrieved. The prospective or retrospective studies focusing on the prognostic role of PODXL expression in cancers were eligible. The endpoints were overall survival (OS), disease-specific survival (DSS) and disease-free survival (DFS).12 studies involving a total of 5,309 patients were identified. The results indicated that high PODXL expression was significantly associated with worse OS when compared to the low PODXL expression (HR=1.76, 95%CI=1.53-2.04, p<0.00001; I2=41%, p=0.08). And similar results were detected in the subgroup analysis of analysis model, ethnicity, sample size, tumor type and antibody type. And the results also showed that high PODXL expression was obviously related to shorter DSS (HR=2.47, 95%CI=1.53-3.99, p=0.0002; I2=66%, p=0.03) and DFS (HR=2.12, 95%CI=1.58-2.85, p<0.00001; I2=19%, p=0.29). In conclusion, it was revealed that high PODXL expression is an unfavorable predictor of OS, DSS and DFS in patients with cancers, and high PODXL expression is a promising prognostic biomarker for cancers, especially for patients in European.
Highlights
Podocalyxin-like protein (PODXL), an important transmembrane glycoprotein belonging to the CD34 family [1], is usually expressed on the apical surface of podocytes and glomerular epithelial cells [2]
Similar results were detected in the subgroup analysis of analysis model, ethnicity, sample size, tumor type and antibody type
The results showed that high PODXL expression was significantly associated with worse overall survival (OS) compared with the low PODXL expression
Summary
Podocalyxin-like protein (PODXL), an important transmembrane glycoprotein belonging to the CD34 family [1], is usually expressed on the apical surface of podocytes and glomerular epithelial cells [2]. It expressed by breast epithelium [3], vascular [4] and haematopoietic progenitors [5]. It was reported that PODXL expression might be associated with prognostic outcomes in patients with cancers, the dispute does exist. Besides the study conducted by Heby et al presented that high PODXL expression was associated with worse recurrence-free survival (RFS) in cohort I. In view of the controversy, the systematic review and meta-analysis was performed to explore the prognostic role of PODXL expression in various cancers
Sign-in/Register to view highlights & summary Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
